Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


New possibilities of ACE inhibitors application on the base of international trails review are presented. Traditional therapy areas of ACE inhibitors (hypertension, heart failure) are well known. However recent studies have shown that ACE inhibitors improve prognosis in patients with clinically proved atherosclerosis. This ACE inhibitor ability is a result of their high vasoprotective effect. It provides new clinical possibilities for their use for slowing a progression of diseases associated with atherosclerosis. However this property can not be extended to all ACE inhibitors. Only ramipril and perindopril have a strong evidence base.

About the Authors

D. V. Nebieridze
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990

A. S. Safarian
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


1. Диагностика и лечение артериальной гипертензии. Третий пересмотр рекомендаций ВНОК и РМОАГ. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2: 1-32.

2. Диагностика и лечение хронической сердечной недостаточности. Национальные рекомендации ВНОК и ОССН (второй пересмотр). Сердечная недостаточность 2007; 8(2):1-35.

3. Yusuf S., Sleight P., Pogue J. et al. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-53.

4. Dagenais G.R., Yusuf S., Bourassa M.G. et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104(5):522-526.

5. Bosch J., Yusuf S., Pogue J. et al. Use oframipril in preventing stroke: double blind randomised trial. BMJ 2002;324(7339):699-702.

6. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable co￾ronary artery disease:randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386); 782-788.

7. Bonner G., Preis S., Schunck U. et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 Suppl 6:S46-56.

8. Busse R., LamontagneD. Endothelium–derived bradykinin is responsible for the increase in calcium produced by angiotensin–converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 1991;344(1):126-9.

9. Anderson T.J., Overhiser R.W., Haber H., Charbonneau F. A comparative study of four anti–hypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998;31 (2 suppl A):327A. Abstract.

10. Braunwald E., Domanski M.J., Fowler S.E. et al. PEAСE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351(20): 2058-2068.

11. Nissen S.E., Tuscu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2226.

12. Диагностика и лечение стабильной стенокардии. Рекомендации ВНОК (второй пересмотр). В Оганов Р.Г., Мамедов М.Н., редакторы. Национальные клинические рекомендации. М.: МЕДИ Экспо; 2009. стр 37-76.

13. Lonn E.M., Yusuf S., Dzavic V. et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001:103(7):919-25.

14. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society ofHypertension (ESH) and ofthe European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.

15. Effects oframipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results oftheHOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.

16. Agodoa L.Y., Appel L., Bakris G.L. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285(21):2719-28.

17. Колос И.П., Мартынюк Т.В., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензин-превращающего фермента рамиприлом и его комбинации с гидрохлортиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследованиеХАРИЗМА.Кардиоваскулярная терапия и профилактика 2008;7(2):65-71.

For citation:

Nebieridze D.V., Safarian A.S. ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM? Rational Pharmacotherapy in Cardiology. 2010;6(4):528-531. (In Russ.)

Views: 335

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)